Mar 2, 2026 07:31AM

Mar 2, 2026 07:30AM

Feb 5, 2026 07:31AM

Feb 5, 2026 07:30AM

Jan 27, 2026 07:31AM

Jan 27, 2026 07:30AM

Jan 6, 2026 07:30AM Cognition Therapeutics publishes Phase 2 results for DLB treatment

Jan 6, 2026 07:30AM

Dec 3, 2025 07:30AM

Dec 3, 2025 07:30AM

Dec 1, 2025 07:31AM

Dec 1, 2025 07:30AM

Nov 6, 2025 07:30AM

Aug 12, 2025 04:00PM Cognition Therapeutics aligns with FDA on Phase 3 trial design for alzheimer's drug

Aug 12, 2025 04:00PM

Aug 7, 2025 04:00PM

Jul 29, 2025 07:30AM

Jul 21, 2025 07:31AM

Jul 21, 2025 07:30AM

Jul 16, 2025 07:31AM

Jul 16, 2025 07:30AM Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC

Jul 14, 2025 07:07AM

Jul 10, 2025 07:31AM

Jul 10, 2025 07:30AM

Jun 26, 2025 06:45AM

Jun 25, 2025 07:30AM

May 7, 2025 07:30AM

Mar 24, 2025 06:42AM Cognition Therapeutics (CGTX) PT Lowered to $5 at H.C. Wainwright

Mar 20, 2025 07:00AM

Feb 26, 2025 07:00AM

Feb 26, 2025 07:00AM

Jan 8, 2025 04:14PM

Dec 18, 2024 07:23AM

Dec 18, 2024 07:22AM

Nov 25, 2024 07:30AM Cognition Therapeutics’ Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer’s Population

Nov 13, 2024 07:30AM

Oct 29, 2024 12:57PM

Oct 29, 2024 12:55PM

Oct 1, 2024 07:30AM

Mar 26, 2024 07:00AM

Oct 16, 2023 07:30AM

Jul 11, 2023 07:30AM Cognition Therapeutics Announces Dosing of First Patient in MAGNIFY Study of Oral CT1812 for Geographic Atrophy Secondary to Dry AMD

May 4, 2023 04:05PM

Apr 19, 2023 07:30AM

Mar 23, 2023 07:31AM

Mar 23, 2023 07:30AM

Mar 23, 2023 07:30AM

Mar 15, 2023 07:31AM

Mar 15, 2023 07:30AM Cognition Therapeutics Announces Development Plans for Oral CT1812 in Geographic Atrophy Secondary to Dry AMD

Feb 22, 2023 08:00AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All